Smolen J.S., Landewé R.B.M., Bijlsma J.W.J., Burmester G.R., Dougados M., Kerschbaumer A. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. https://doi.org/10.1136/annrheumdis-2019-216655..
DOI: 10.1136/annrheumdis-2019-216655
Smolen J.S., Aletaha D., Bijlsma J.W., Breedveld F.C., Boumpas D., Burmester G. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–637. https://doi.org/10.1136/ard.2009.123919..
DOI: 10.1136/ard.2009.123919
van Vollenhoven R.F., Fleischmann R., Cohen S., Lee E.B., García Meijide J.A., Wagner S. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508–519. https://doi.org/10.1056/NEJMoa1112072..
DOI: 10.1056/NEJMoa1112072
van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27(1):261–263. Available at: https://pubmed.ncbi.nlm.nih.gov/10648051.https://pubmed.ncbi.nlm.nih.gov/10648051
van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27(1):261–263. Available at: https://pubmed.ncbi.nlm.nih.gov/10648051.https://pubmed.ncbi.nlm.nih.gov/10648051
van der Heijde D., Tanaka Y., Fleischmann R., Keystone E., Kremer J., Zerbini C. et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-fourmonth phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559–570. https://doi.org/10.1002/art.37816..
DOI: 10.1002/art.37816
Fleischmann R., Kremer J., Cush J., Schulze-Koops H., Connell C.A., Bradley J.D. et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495–507. https://doi.org/10.1056/NEJMoa1109071..
DOI: 10.1056/NEJMoa1109071
Kremer J., Li Z.G., Hall S., Fleischmann R., Genovese M., Martin-Mola E. et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159(4):253–261. https://doi.org/10.7326/0003-4819-159-4-201308200-00006..
DOI: 10.7326/0003-4819-159-4-201308200-00006
Burmester G.R., Blanco R., Charles-Schoeman C., Wollenhaupt J., Zerbini C., Benda B. et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451–460. https://doi.org/10.1016/S0140-6736(12)61424-X..
DOI: 10.1016/S0140-6736(12)61424-X
Lee E.B., Fleischmann R., Hall S., Wilkinson B., Bradley J.D., Gruben D. et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377–2386. https://doi.org/10.1056/NEJMoa1310476..
DOI: 10.1056/NEJMoa1310476
Каратеев А.Е., Погожева Е.Ю., Амирджанова В.Н., Филатова Е.С., Лила А.М., Мазуров В.И. и др. Оценка эффективности тофацитиниба при ревматоидном артрите в реальной клинической практике: взаимосвязь между снижением боли в первые 4 недели и активностью заболевания через 3–6 месяцев. Научно-практическая ревматология. 2021;(4):394–400. https://doi.org/10.47360/1995-4484-2021-394-400..
DOI: 10.47360/1995-4484-2021-394-400
Авдеева А.С., Мисиюк А.С., Сатыбалдыев А.М., Лукина Г.В., Сороцкая В.Н., Жиляев Е.В. и др. Анализ результатов терапии тофацитинибом в реальной клинической практике (по данным Общероссийского регистра больных артритом ОРЕЛ). Научно-практическая ревматология. 2020;(3):262–267. Режим доступа: https://rsp.mediar-press.net/rsp/article/view/2891.https://rsp.mediar-press.net/rsp/article/view/2891
Авдеева А.С., Мисиюк А.С., Сатыбалдыев А.М., Лукина Г.В., Сороцкая В.Н., Жиляев Е.В. и др. Анализ результатов терапии тофацитинибом в реальной клинической практике (по данным Общероссийского регистра больных артритом ОРЕЛ). Научно-практическая ревматология. 2020;(3):262–267. Режим доступа: https://rsp.mediar-press.net/rsp/article/view/2891.https://rsp.mediar-press.net/rsp/article/view/2891
Мазуров В.И., Трофимов Е.А., Самигуллина Р.Р., Гайдукова И.З. Место тофацитиниба в стратегии лечения ревматоидного артрита. Научно-практическая ревматология. 2018;(2):152–156. Режим доступа: https://rsp.mediar-press.net/rsp/article/view/2519.https://rsp.mediar-press.net/rsp/article/view/2519
Мазуров В.И., Трофимов Е.А., Самигуллина Р.Р., Гайдукова И.З. Место тофацитиниба в стратегии лечения ревматоидного артрита. Научно-практическая ревматология. 2018;(2):152–156. Режим доступа: https://rsp.mediar-press.net/rsp/article/view/2519.https://rsp.mediar-press.net/rsp/article/view/2519
Wollenhaupt J., Lee E.B., Curtis J.R., Silverfield J., Terry K., Soma K. et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21(1):89. https://doi.org/10.1186/s13075-019-1866-2..
DOI: 10.1186/s13075-019-1866-2
Pope J.E., Keystone E., Jamal S., Wang L., Fallon L., Woolcott J. et al. Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years. ACR Open Rheumatol. 2019;1(2):73–82. https://doi.org/10.1002/acr2.1010..
DOI: 10.1002/acr2.1010
Ahadieh S., Checchio T., Tensfeldt T., French J., Krishnaswami S., Riese R. et al. Meta-Analysis of Malignancies, Serious Infections, and Serious Adverse Events with Tofacitinib or Biologic Treatment in Rheumatoid Arthritis Clinical Trials. Arthr Rheum. 2012;64(S10):S726. Available at: https://acrabstracts.org/abstract/meta-analysis-of-malignancies-seriousinfections-and-serious-adverse-events-with-tofacitinib-or-biologic-treatment-in-rheumatoid-arthritis-clinical-trials.https://acrabstracts.org/abstract/meta-analysis-of-malignancies-seriousinfections-and-serious-adverse-events-with-tofacitinib-or-biologic-treatment-in-rheumatoid-arthritis-clinical-trials
Ahadieh S., Checchio T., Tensfeldt T., French J., Krishnaswami S., Riese R. et al. Meta-Analysis of Malignancies, Serious Infections, and Serious Adverse Events with Tofacitinib or Biologic Treatment in Rheumatoid Arthritis Clinical Trials. Arthr Rheum. 2012;64(S10):S726. Available at: https://acrabstracts.org/abstract/meta-analysis-of-malignancies-seriousinfections-and-serious-adverse-events-with-tofacitinib-or-biologic-treatment-in-rheumatoid-arthritis-clinical-trials.https://acrabstracts.org/abstract/meta-analysis-of-malignancies-seriousinfections-and-serious-adverse-events-with-tofacitinib-or-biologic-treatment-in-rheumatoid-arthritis-clinical-trials
Cohen S.B., Tanaka Y., Mariette X., Curtis J.R., Lee E.B., Nash P. et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76(7):1253–1262. https://doi.org/10.1136/annrheumdis-2016-210457..
DOI: 10.1136/annrheumdis-2016-210457
Чичасова Н.В., Лила А.М. Эффективность и безопасность тофацитиниба в лечении ревматоидного артрита: итоги 10-летнего применения. Медицинский совет. 2022;(21):139–145. https://doi.org/10.21518/2079701X-2022-16-21-139-145..
DOI: 10.21518/2079701X-2022-16-21-139-145
Чичасова Н.В., Лила А.М. Эффективность и безопасность тофацитиниба в лечении ревматоидного артрита: итоги 10-летнего применения. Медицинский совет. 2022;(21):139–145. https://doi.org/10.21518/2079701X-2022-16-21-139-145..
DOI: 10.21518/2079-701X-2022-16-21-139-145
Charles-Schoeman C., Wicker P., Sechtem U., Gonzalez-Gay M.A., Wood S., Boy M. et.al. THU0136 Cardiovascular safety findings in rheumatoid arthritis patients treated with tofacitinib (CP-690,550), a novel, oral jak inhibitor. Ann Rheum Dis. 2012;71(Suppl. 3):201. Available at: https://ard.bmj.com/content/annrheumdis/71/Suppl_3/201.1.full.pdf.https://ard.bmj.com/content/annrheumdis/71/Suppl_3/201.1.full.pdf
Charles-Schoeman C., Wicker P., Sechtem U., Gonzalez-Gay M.A., Wood S., Boy M. et.al. THU0136 Cardiovascular safety findings in rheumatoid arthritis patients treated with tofacitinib (CP-690,550), a novel, oral jak inhibitor. Ann Rheum Dis. 2012;71(Suppl. 3):201. Available at: https://ard.bmj.com/content/annrheumdis/71/Suppl_3/201.1.full.pdf.https://ard.bmj.com/content/annrheumdis/71/Suppl_3/201.1.full.pdf
Charles-Schoeman C., DeMasi R., Valdez H., Soma K., Hwang L.J., Boy M.G. et al. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2019;71(9):1450–1459. https://doi.org/10.1002/art.40911..
DOI: 10.1002/art.40911
Ytterberg S.R., Bhatt D.L., Mikuls T.R., Koch G.G., Fleischmann R., Rivas J.L. et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(4):316–326. https://doi.org/10.1056/NEJMoa2109927..
DOI: 10.1056/NEJMoa2109927
Smolen J.S., Landewé R.B.M., Bergstra S.A., Kerschbaumer A., Sepriano A., Aletaha D. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18. https://doi.org/10.1136/ard-2022-223356..
DOI: 10.1136/ard-2022-223356
Huang S., Cai T., Weber B.N., He Z., Dahal K.P., Hong C. et.al. Association Between Inflammation, Incident Heart Failure, and Heart Failure Subtypes in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2023;75(5):1036–1045. https://doi.org/10.1002/acr.24804..
DOI: 10.1002/acr.24804
Biskup M., Biskup W., Majdan M., Targońska-Stępniak B. Cardiovascular system changes in rheumatoid arthritis patients with continued low disease activity. Rheumatol Int. 2018;38(7):1207–1215. https://doi.org/10.1007/s00296-018-4053-x..
DOI: 10.1007/s00296-018-4053-x
Farhat H., Irfan H., Muthiah K., Pallipamu N., Taheri S., Thiagaraj S.S. et al. Increased Risk of Cardiovascular Diseases in Rheumatoid Arthritis: A Systematic Review. Cureus. 2022;14(12):e32308. https://doi.org/10.7759/cureus.32308..
DOI: 10.7759/cureus.32308
Taylor P.C., Weinblatt M.E., Burmester G.R., Rooney T.P., Witt S., Walls C.D. et al. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. Arthritis Rheumatol. 2019;71(7):1042–1055. https://doi.org/10.1002/art.40841..
DOI: 10.1002/art.40841
Ungprasert P., Srivali N., Wijarnpreecha K., Charoenpong P., Knight E.L. Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: a systematic review and meta-analysis. Rheumatology (Oxford). 2015;54(4):736–742. https://doi.org/10.1093/rheumatology/keu408..
DOI: 10.1093/rheumatology/keu408
Dikranian A.H., Gonzalez-Gay M.A., Wellborne F., Álvaro-Gracia J.M., Takiya L., Stockert L. et al. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. RMD Open. 2022;8(1):e002103. https://doi.org/10.1136/rmdopen-2021-002103..
DOI: 10.1136/rmdopen-2021-002103
Federico L.E., Johnson T.M., England B.R., Wysham K.D., George M.D., Sauer B. et al. Circulating Adipokines and Associations With Incident Cardiovascular Disease in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2023;75(4):768–777. https://doi.org/10.1002/acr.24885..
DOI: 10.1002/acr.24885
Khosrow-Khavar F., Kim S.C., Lee H., Lee S.B., Desai R.J. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022;81(6):798–804. https://doi.org/10.1136/annrheumdis-2021-221915..
DOI: 10.1136/annrheumdis-2021-221915
Kremer J.M., Bingham C.O. 3rd, Cappelli L.C., Greenberg J.D., Madsen A.M., Geier J. et al. Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry. ACR Open Rheumatol. 2021;3(3):173–184. https://doi.org/10.1002/acr2.11232..
DOI: 10.1002/acr2.11232
Iwamoto N., Sato S., Kurushima S., Michitsuji T., Nishihata S., Okamoto M. et al. Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis. Arthritis Res Ther. 2021;23(1):197. https://doi.org/10.1186/s13075-021-02582-z..
DOI: 10.1186/s13075-021-02582-z
Tóth L., Juhász M.F., Szabó L., Abada A., Kiss F., Hegyi P. et al. Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients. Int J Mol Sci. 2022;23(3):1246. https://doi.org/10.3390/ijms23031246..
DOI: 10.3390/ijms23031246
Bergstra S.A., Sepriano A., Kerschbaumer A., van der Heijde D., Caporali R., Edwards C.J. et al. Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023;82(1):81–94. https://doi.org/10.1136/ard-2022-223358..
DOI: 10.1136/ard-2022-223358
Fraenkel L., Bathon J.M., England B.R., St Clair E.W., Arayssi T., Carandang K. et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73(7):1108–1123. https://doi.org/10.1002/art.41752..
DOI: 10.1002/art.41752